THE FOUNDATION FOR AIDS RESEARCH: Form 990, tax year 2010

View the entire original 990 at ProPublica ↗

Organization: THE FOUNDATION FOR AIDS RESEARCH (EIN 13-3163817)
Tax period: 2010-10-01 to 2011-09-30
Filed: 2012-06-19
IRS object ID: 201231719349300673
Schema version: 2010v3.7
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Timestamp	2012-06-19T17:06:58-04:00	Timestamp
Tax Period End Date	2011-09-30	TaxPeriodEndDate

Preparer Firm PreparerFirm

Preparer Firm Business Name PreparerFirmBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	GRANT THORNTON LLP	BusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

Field	Value	IRS element (for citing)
Address Line1	666 THIRD AVENUE	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	100174011	ZIPCode

Field	Value	IRS element (for citing)
Return Type	990	ReturnType
Tax Period Begin Date	2010-10-01	TaxPeriodBeginDate

Filer Filer

Field	Value	IRS element (for citing)
EIN	133163817	EIN

Name Name

Field	Value	IRS element (for citing)
Business Name Line1	THE FOUNDATION FOR AIDS RESEARCH	BusinessNameLine1

Field	Value	IRS element (for citing)
Name Control	FOUN	NameControl
Phone	2128061600	Phone

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 wall street 13TH FLOOR	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	100053908	ZIPCode

Officer Officer

Field	Value	IRS element (for citing)
Name	Bradley Jensen	Name
Title	treasurer, cfo	Title
Date Signed	2012-06-19	DateSigned

Preparer Preparer

Field	Value	IRS element (for citing)
Phone	2125990100	Phone

Field	Value	IRS element (for citing)
Tax Year	2010	TaxYear
Build TS	2016-02-24 21:20:13Z	BuildTS

Form 990 IRS990

Doing Business As DoingBusinessAs

Field	Value	IRS element (for citing)
Business Name Line1	amfar	BusinessNameLine1

Field	Value	IRS element (for citing)
Name Of Principal Officer Person	KEVIN FROST	NameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1
City	new york	City
State	NY	State
ZIP Code	10005	ZIPCode

Field	Value	IRS element (for citing)
Gross Receipts	44969834	GrossReceipts
Group Return For Affiliates	false	GroupReturnForAffiliates
Organization501c3	X	Organization501c3
Web Site	WWW.AMFAR.ORG	WebSite
Type Of Organization Corporation	X	TypeOfOrganizationCorporation
Year Formation	1983	YearFormation
State Legal Domicile	NY	StateLegalDomicile
Activity Or Mission Description	amfar is dedicated to ending the global aids epidemic through innovative research.	ActivityOrMissionDescription
Nbr Voting Members Governing Body	19	NbrVotingMembersGoverningBody
Nbr Independent Voting Members	19	NbrIndependentVotingMembers
Total Nbr Employees	84	TotalNbrEmployees
Total Nbr Volunteers	145	TotalNbrVolunteers
Total Gross UBI	0	TotalGrossUBI
Net Unrelated Business Txbl Income	0	NetUnrelatedBusinessTxblIncome
Contributions Grants Prior Year	21965059	ContributionsGrantsPriorYear
Contributions Grants Current Year	31689016	ContributionsGrantsCurrentYear
Program Service Revenue Prior Year	0	ProgramServiceRevenuePriorYear
Program Service Revenue CY	0	ProgramServiceRevenueCY
Investment Income Prior Year	506704	InvestmentIncomePriorYear
Investment Income Current Year	885610	InvestmentIncomeCurrentYear
Other Revenue Prior Year	2889638	OtherRevenuePriorYear
Other Revenue Current Year	-5259666	OtherRevenueCurrentYear
Total Revenue Prior Year	25361401	TotalRevenuePriorYear
Total Revenue Current Year	27314960	TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year	4604199	GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY	6694401	GrantsAndSimilarAmntsCY
Benefits Paid To Members Prior Year	0	BenefitsPaidToMembersPriorYear
Benefits Paid To Members CY	0	BenefitsPaidToMembersCY
Salaries Etc Prior Year	7735764	SalariesEtcPriorYear
Salaries Etc Current Year	8447012	SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year	483987	TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY	403813	TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year	4438779	TotalFundrsngExpCurrentYear
Other Expense Prior Year	10930086	OtherExpensePriorYear
Other Expenses Current Year	10565187	OtherExpensesCurrentYear
Total Expenses Prior Year	23754036	TotalExpensesPriorYear
Total Expenses Current Year	26110413	TotalExpensesCurrentYear
Revenues Less Expenses Prior Year	1607365	RevenuesLessExpensesPriorYear
Revenues Less Expenses CY	1204547	RevenuesLessExpensesCY
Total Assets BOY	35804430	TotalAssetsBOY
Total Assets EOY	38004315	TotalAssetsEOY
Total Liabilities BOY	5238664	TotalLiabilitiesBOY
Total Liabilities EOY	6564234	TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY	30565766	NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY	31440081	NetAssetsOrFundBalancesEOY
Info In Schedule O Part III	X	InfoInScheduleOPartIII
Mission Description	The Foundation for AIDS Research is an international not-for-profit organization incorporated in New York in 1989. amfAR was formed through the unification in 1985 of two not-for-profit organizations, the AIDS Medical Foundation ("AMF"), incorporated in New York in April 1983, and the National AIDS Research Foundation, incorporated in California in August 1985. First based in California, amfAR transferred its legal domicile to New York in 1989, using the initial incorporation documents of AMF, making it AMF's legal successor. amfAR has offices in New York, NY, Washington, D.C., and Bangkok, Thailand. On March 7, 2005, the board of trustees of the American Foundation for AIDS Research approved a change in legal name to "The Foundation for AIDS Research." On October 18, 2005, the New York State Department of State approved this change. In addition, the Foundation has secured approval for Doing Business As (DBA) the following: - American Foundation for AIDS Research - amfAR - AIDS Researc	MissionDescription
Significant New Program Services	false	SignificantNewProgramServices
Significant Change	false	SignificantChange
Expense	7511991	Expense
Grants	3125468	Grants
Revenue	0	Revenue
Description	RESEARCH: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. For further details, see Schedule o.	Description

Activity2 Activity2

Field	Value	IRS element (for citing)
Expense	5915106	Expense
Grants	2561037	Grants
Revenue	0	Revenue
Description	TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 22 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. Eight papers based on the network's research were published in U.S. and international scientific journals in 2011. For further details, see Schedule o.	Description

Activity3 Activity3

Field	Value	IRS element (for citing)
Expense	2800605	Expense
Grants	0	Grants
Revenue	0	Revenue
Description	EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. For further details, see Schedule O.	Description

Activity Other ActivityOther (2 entries)

ExpenseExpense	GrantsGrants	RevenueRevenue	DescriptionDescription
1851360	852896	0	MSM Initiative
1616906	155000	0	public policy

Field	Value	IRS element (for citing)
Total Of Other Program Service Exp	3468266	TotalOfOtherProgramServiceExp
Total Of Other Program Service Grnt	1007896	TotalOfOtherProgramServiceGrnt
Total Of Other Program Service Rev	0	TotalOfOtherProgramServiceRev
Total Program Service Expense	19695968	TotalProgramServiceExpense
Described In501 C3	true	DescribedIn501C3
Schedule B Required	true	ScheduleBRequired
Political Activities	false	PoliticalActivities
Lobbying Activities	true	LobbyingActivities
Donor Advised Funds	false	DonorAdvisedFunds
Conservation Easements	false	ConservationEasements
Collections Of Art	true	CollectionsOfArt
Credit Counseling	false	CreditCounseling
Term Or Permanent Endowments	true	TermOrPermanentEndowments
Report Land Bldg Equip	true	ReportLandBldgEquip
Report Invest Oth Securities	false	ReportInvestOthSecurities
Report Prog Rel Invest	false	ReportProgRelInvest
Report Other Assets	false	ReportOtherAssets
Report Other Liabilities	true	ReportOtherLiabilities
Report Fin48 Footnote	true	ReportFin48Footnote
Independent Audit Financial Stmt	true	IndependentAuditFinancialStmt
Consolidated Audit Financial Stmt	false	ConsolidatedAuditFinancialStmt
School	false	School
Foreign Office	true	ForeignOffice
Foreign Activities	true	ForeignActivities
More Than5000 K To Organizations	true	MoreThan5000KToOrganizations
More Than5000 K To Individuals	false	MoreThan5000KToIndividuals
Professional Fundraising	true	ProfessionalFundraising
Fundraising Activities	true	FundraisingActivities
Gaming	false	Gaming
Hospital	false	Hospital
Grants To Organizations	true	GrantsToOrganizations
Grants To Individuals	false	GrantsToIndividuals
Schedule J Required	true	ScheduleJRequired
Tax Exempt Bonds	false	TaxExemptBonds
Excess Benefit Transaction	false	ExcessBenefitTransaction
Prior Excess Benefit Transaction	false	PriorExcessBenefitTransaction
Loan To Officer Or DQP	false	LoanToOfficerOrDQP
Grant To Related Person	false	GrantToRelatedPerson
Bsnss Rltnshp With Organization	false	BsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family Member	false	BsnssRltnshpThruFamilyMember
Officer Entity With Bsnss Rltnshp	false	OfficerEntityWithBsnssRltnshp
Deductible Non Cash Contributions	true	DeductibleNonCashContributions
Deductible Contributions Of Art	false	DeductibleContributionsOfArt
Terminated	false	Terminated
Partial Liquidation	false	PartialLiquidation
Disregarded Entity	false	DisregardedEntity
Related Entity	false	RelatedEntity
Related Org Controlled Entity	false	RelatedOrgControlledEntity
Transaction Related Entity	false	TransactionRelatedEntity
Transfers To Exempt Non Chrtbl Org	false	TransfersToExemptNonChrtblOrg
Activities Conducted Partnership	false	ActivitiesConductedPartnership
Schedule O Required	true	ScheduleORequired
Number Forms Transmitted With1096	83	NumberFormsTransmittedWith1096
Number W2 G Included	0	NumberW2GIncluded
Compliance With Backup Witholding	true	ComplianceWithBackupWitholding
Number Of Employees	84	NumberOfEmployees
Employment Tax Returns Filed	true	EmploymentTaxReturnsFiled
Unrelated Business Income	false	UnrelatedBusinessIncome
Foreign Financial Account	true	ForeignFinancialAccount
Name Of Foreign Country	TH	NameOfForeignCountry
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTrans
Taxable Party Notification	false	TaxablePartyNotification
Non Deductible Contributions	false	NonDeductibleContributions
Quid Pro Quo Contributions	true	QuidProQuoContributions
Quid Pro Quo Disclosure	true	QuidProQuoDisclosure
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOf
Funds To Pay Premiums	false	FundsToPayPremiums
Premiums Paid	false	PremiumsPaid
Indoor Tanning Services	false	IndoorTanningServices
Info In Schedule O Part VI	X	InfoInScheduleOPartVI
Nbr Voting Governing Body Members	19	NbrVotingGoverningBodyMembers
Number Independent Voting Members	19	NumberIndependentVotingMembers
Family Or Business Relationship	false	FamilyOrBusinessRelationship
Delegation Of Management Duties	false	DelegationOfManagementDuties
Changes To Organizing Docs	false	ChangesToOrganizingDocs
Material Diversion Or Misuse	false	MaterialDiversionOrMisuse
Members Or Stockholders	false	MembersOrStockholders
Election Of Board Members	false	ElectionOfBoardMembers
Decisions Subject To Approval	false	DecisionsSubjectToApproval
Minutes Of Governing Body	true	MinutesOfGoverningBody
Minutes Of Committees	true	MinutesOfCommittees
Officer Mailing Address	false	OfficerMailingAddress
Local Chapters	false	LocalChapters
Form990 Provided To Governing Body	true	Form990ProvidedToGoverningBody
Conflict Of Interest Policy	true	ConflictOfInterestPolicy
Annual Disclosure Covered Persons	true	AnnualDisclosureCoveredPersons
Regular Monitoring Enforcement	true	RegularMonitoringEnforcement
Whistleblower Policy	true	WhistleblowerPolicy
Document Retention Policy	true	DocumentRetentionPolicy
Compensation Process CEO	true	CompensationProcessCEO
Compensation Process Other	true	CompensationProcessOther
Investment In Joint Venture	false	InvestmentInJointVenture
States Where Copy Of Return Is Filed	AL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AZ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CO	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	FL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	GA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	HI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	IL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	LA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	ME	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MD	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NH	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NJ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NM	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OH	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	PA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	RI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	SC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	TN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	UT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	VA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WV	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WI	StatesWhereCopyOfReturnIsFiled
Own Website	X	OwnWebsite
Upon Request	X	UponRequest

The Books Are In Care Of TheBooksAreInCareOf

Field	Value	IRS element (for citing)
Name Person	BRADLEY JENSEN	NamePerson
Telephone Number	2128061703	TelephoneNumber

Address US AddressUS

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1
City	new york	City
State	NY	State
ZIP Code	100053908	ZIPCode

Form990 Part VII Section A Form990PartVIISectionA (40 entries)

TitleTitle	Average Hours Per WeekAverageHoursPerWeek	Individual Trustee Or DirectorIndividualTrusteeOrDirector	OfficerOfficer	Reportable Comp From OrganizationReportableCompFromOrganization	Reportable Comp From Related OrgsReportableCompFromRelatedOrgs	Other CompensationOtherCompensation	Key EmployeeKeyEmployee	Highest Compensated EmployeeHighestCompensatedEmployee
Dame Elizabeth Taylorthru 311
Founding Intl Chairman	1.0	X	X	0	0	0
Mathilde Krim PhD
Founding Chairman	1.0	X	X	0	0	0
Kenneth Cole
Chairman of the Board	1.0	X	X	0	0	0
Patricia J Matson
Vice Chairman	1.0	X	X	0	0	0
John C Simons
Vice Chairman	1.0	X	X	0	0	0
Wallace Sheft CPA
Treasurer	1.0	X	X	0	0	0
Mervyn F Silverman MDMPH
Secretary	1.0	X	X	0	0	0
Arlen H Andelson
Trustee	1.0	X		0	0	0
Harry Belafonte
Trustee (NON-voting)	1.0	X		0	0	0
David Bohnett
Trustee	1.0	X		0	0	0
Zev Braun
Trustee (non-voting)	1.0	X		0	0	0
Jonathan S Canno
Trustee	1.0	X		0	0	0
Donald Capoccia
Trustee (NON-VOTING)	1.0	X		0	0	0
R Martin Chavez PhD
Trustee	1.0	X		0	0	0
Jane B Eisner
Trustee (NON-voting)	1.0	X		0	0	0
T Ryan Greenawalt
Trustee	1.0	X		0	0	0
Regan Hofmann
Trustee	1.0	X		0	0	0
Michael J Klingensmith
Trustee	1.0	X		0	0	0
Michele V McNeill PharmD
Trustee (NON-Voting)	1.0	X		0	0	0
Richard H Metzner
Trustee	1.0	X		0	0	0
Edward Milstein
Trustee	1.0	X		0	0	0
Cindy Rachofsky
Trustee	1.0	X		0	0	0
Vincent A Roberti
Trustee	1.0	X		0	0	0
Bill Roedy
Trustee	1.0	X		0	0	0
Alan D Schwartz
Trustee (NON-VOTING)	1.0	X		0	0	0
Diana L Taylor
Trustee	1.0	X		0	0	0
Kevin Wendle
Trustee (NON-VOTING)	1.0	X		0	0	0
Kevin Frost
Chief Executive Officer	40.0		X	343450	0	44502
Bradley Jensen
ASST Treasurer, CFO	40.0		X	191604	0	39664
John F Logan JD PhD
ASST Secretary, VP & GC	40.0		X	179618	0	21376
Rowena Johnston
ASST Secretary, VP OF RESEARCH	40.0		X	145204	0	18490
Edward Donnelly
ASST Treasurer, ControlleR	40.0		X	135171	0	14779
Gregory L Boroff
Vice President of Development	40.0			207364	0	23175	X
Christopher Collins
Vice President, Public Policy	40.0			165536	0	36334	X
Annette Sohn
Vice President, TREAT Asia	40.0			172673	0	15849	X
Eric Muscatell
Director, Philanthropy	40.0			146674	0	18680		X
Andrew McInnes
Director, Publications	40.0			123252	0	34404		X
Anthony Ancona
Vice President, Human Resource	40.0			143131	0	10241		X
Susan Doster
Chief Technology Officer	40.0			127277	0	16423		X
AnnMarie Shannahan
Vice President, Public Info	40.0			122379	0	6022		X

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	2203333	TotalReportableCompFromOrg
Total Reportable Comp Frm Rltd Orgs	0	TotalReportableCompFrmRltdOrgs
Total Other Compensation	299939	TotalOtherCompensation
Number Individuals GT100 K	16	NumberIndividualsGT100K
Formers Listed	false	FormersListed
Total Comp GT150 K	true	TotalCompGT150K
Compensation From Other Sources	false	CompensationFromOtherSources

Contractor Compensation ContractorCompensation (5 entries)

Address Line1AddressOfContractor/AddressUS/AddressLine1	CityAddressOfContractor/AddressUS/City	StateAddressOfContractor/AddressUS/State	ZIP CodeAddressOfContractor/AddressUS/ZIPCode	Description Of ServicesDescriptionOfServices	CompensationCompensation
aab production
64 allen street 5th floor	NEW YORK	NY	10002	events production	243200
grant thornton llp
1901 w meyers road suite 455	OAKBROOK TERRACE	IL	60181	accounting & audit	152288
downey mcgrath group inc
27 west 24th street suite 900	NEW YORK	NY	10010	program tech support	127500
Global Health Institute
3403 rolling court	CHEVY CHASE	MD	20815	consulting	120000
john mini consulting inc
707 savannah road	LEWES	DE	19958	direct mail	116350

Field	Value	IRS element (for citing)
Number Of Contractors GT100 K	8	NumberOfContractorsGT100K
Federated Campaigns	388831	FederatedCampaigns
Fundraising Events	17594927	FundraisingEvents
Government Grants	5432260	GovernmentGrants
All Other Contributions	8272998	AllOtherContributions
Noncash Contributions	262516	NoncashContributions
Total Contributions	31689016	TotalContributions
Total Program Service Revenue	0	TotalProgramServiceRevenue

Investment Income InvestmentIncome

Field	Value	IRS element (for citing)
Total Revenue Column	737166	TotalRevenueColumn
Exclusion	$737,166	ExclusionAmount

Income From Invest Bond Proceeds IncomeFromInvestBondProceeds

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Royalties Revenue RoyaltiesRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	214797	TotalRevenueColumn
Exclusion	$214,797	ExclusionAmount

Gross Amount Sales Assets GrossAmountSalesAssets

Field	Value	IRS element (for citing)
Securities	10593526	Securities

Less Cost Oth Basis Sales Expenses LessCostOthBasisSalesExpenses

Field	Value	IRS element (for citing)
Securities	10445082	Securities

Gain Or Loss GainOrLoss

Field	Value	IRS element (for citing)
Securities	148444	Securities

Net Gain Or Loss Investments NetGainOrLossInvestments

Field	Value	IRS element (for citing)
Total Revenue Column	148444	TotalRevenueColumn
Exclusion	$148,444	ExclusionAmount

Field	Value	IRS element (for citing)
Gross Income Fundraising Events	1452830	GrossIncomeFundraisingEvents
Cntrbtns Rprtd Fundraising Events	17594927	CntrbtnsRprtdFundraisingEvents
Fundraising Direct Expenses	7203604	FundraisingDirectExpenses

Net Income From Fundraising Events NetIncomeFromFundraisingEvents

Field	Value	IRS element (for citing)
Total Revenue Column	-5750774	TotalRevenueColumn
Exclusion	-$5,750,774	ExclusionAmount

Net Income From Gaming NetIncomeFromGaming

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	242362	GrossSalesOfInventory
Cost Of Goods Sold	6188	CostOfGoodsSold

Net Income Or Loss NetIncomeOrLoss

Field	Value	IRS element (for citing)
Total Revenue Column	236174	TotalRevenueColumn
Exclusion	$236,174	ExclusionAmount

Other Revenue Misc OtherRevenueMisc (2 entries)

DescriptionDescription	Business CodeBusinessCode	Total Revenue ColumnTotalRevenueColumn	ExclusionExclusionAmount
LIST RENTALS	900099	26881	$26,881
MISCELLANEOUS INCOME	900099	13256	$13,256

Field	Value	IRS element (for citing)
Total Other Revenue	40137	TotalOtherRevenue

Total Revenue TotalRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	27314960	TotalRevenueColumn
Unrelated Business Revenue	0	UnrelatedBusinessRevenue
Exclusion	-$4,374,056	ExclusionAmount

Grants To Domestic Orgs GrantsToDomesticOrgs

Field	Value	IRS element (for citing)
Total	2510544	Total
Program Services	2510544	ProgramServices

Grants To Domestic Individuals GrantsToDomesticIndividuals

Field	Value	IRS element (for citing)
Total	0	Total

Foreign Grants ForeignGrants

Field	Value	IRS element (for citing)
Total	4183857	Total
Program Services	4183857	ProgramServices

Benefits To Members BenefitsToMembers

Field	Value	IRS element (for citing)
Total	0	Total

Comp Current Officers Directors CompCurrentOfficersDirectors

Field	Value	IRS element (for citing)
Total	2390379	Total
Program Services	1607250	ProgramServices
Management And General	280435	ManagementAndGeneral
Fundraising	502694	Fundraising

Comp Disqual Persons CompDisqualPersons

Field	Value	IRS element (for citing)
Total	0	Total

Other Salaries And Wages OtherSalariesAndWages

Field	Value	IRS element (for citing)
Total	4760549	Total
Program Services	3528307	ProgramServices
Management And General	233963	ManagementAndGeneral
Fundraising	998279	Fundraising

Pension Plan Contributions PensionPlanContributions

Field	Value	IRS element (for citing)
Total	177016	Total
Program Services	42792	ProgramServices
Management And General	91249	ManagementAndGeneral
Fundraising	42975	Fundraising

Other Employee Benefits OtherEmployeeBenefits

Field	Value	IRS element (for citing)
Total	702348	Total
Program Services	275602	ProgramServices
Management And General	266808	ManagementAndGeneral
Fundraising	159938	Fundraising

Payroll Taxes PayrollTaxes

Field	Value	IRS element (for citing)
Total	416720	Total
Program Services	181953	ProgramServices
Management And General	121905	ManagementAndGeneral
Fundraising	112862	Fundraising

Fees For Services Management FeesForServicesManagement

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Legal FeesForServicesLegal

Field	Value	IRS element (for citing)
Total	61465	Total
Program Services	56102	ProgramServices
Management And General	5363	ManagementAndGeneral

Fees For Services Accounting FeesForServicesAccounting

Field	Value	IRS element (for citing)
Total	204790	Total
Management And General	204790	ManagementAndGeneral

Fees For Services Lobbying FeesForServicesLobbying

Field	Value	IRS element (for citing)
Total	62250	Total
Program Services	62250	ProgramServices

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	403813	Total
Fundraising	403813	Fundraising

Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees

Field	Value	IRS element (for citing)
Total	123027	Total
Management And General	123027	ManagementAndGeneral

Fees For Services Other FeesForServicesOther

Field	Value	IRS element (for citing)
Total	1390134	Total
Program Services	819672	ProgramServices
Management And General	61904	ManagementAndGeneral
Fundraising	508558	Fundraising

Advertising Advertising

Field	Value	IRS element (for citing)
Total	54170	Total
Program Services	43460	ProgramServices
Management And General	149	ManagementAndGeneral
Fundraising	10561	Fundraising

Office Expenses OfficeExpenses

Field	Value	IRS element (for citing)
Total	86473	Total
Program Services	53779	ProgramServices
Management And General	9844	ManagementAndGeneral
Fundraising	22850	Fundraising

Information Technology InformationTechnology

Field	Value	IRS element (for citing)
Total	36774	Total
Program Services	25194	ProgramServices
Management And General	5126	ManagementAndGeneral
Fundraising	6454	Fundraising

Royalties Royalties

Field	Value	IRS element (for citing)
Total	0	Total

Occupancy Occupancy

Field	Value	IRS element (for citing)
Total	1186330	Total
Program Services	810213	ProgramServices
Management And General	164857	ManagementAndGeneral
Fundraising	211260	Fundraising

Travel Travel

Field	Value	IRS element (for citing)
Total	803002	Total
Program Services	492998	ProgramServices
Management And General	9977	ManagementAndGeneral
Fundraising	300027	Fundraising

Travel Entrtnmnt Public Officials TravelEntrtnmntPublicOfficials

Field	Value	IRS element (for citing)
Total	0	Total

Conferences Meetings ConferencesMeetings

Field	Value	IRS element (for citing)
Total	976913	Total
Program Services	852029	ProgramServices
Management And General	14522	ManagementAndGeneral
Fundraising	110362	Fundraising

Interest Interest

Field	Value	IRS element (for citing)
Total	0	Total

Payments To Affiliates PaymentsToAffiliates

Field	Value	IRS element (for citing)
Total	0	Total

Depreciation Depletion DepreciationDepletion

Field	Value	IRS element (for citing)
Total	250337	Total
Program Services	171695	ProgramServices
Management And General	34935	ManagementAndGeneral
Fundraising	43707	Fundraising

Insurance Insurance

Field	Value	IRS element (for citing)
Total	161705	Total
Program Services	110784	ProgramServices
Management And General	22542	ManagementAndGeneral
Fundraising	28379	Fundraising

Other Expenses OtherExpenses (5 entries)

DescriptionDescription	TotalTotal	Program ServicesProgramServices	Management And GeneralManagementAndGeneral	FundraisingFundraising
PROGRAM MATERIALS	2179167	2179167	0	0
POSTAGE & SHIPPING	668406	284033	2725	381648
PROGRAM TECHNICAL SUPPORT	591246	591246	0	0
PRINTING	563260	215138	0	348122
BAD DEBT EXPENSE	262348	179723	36586	46039

All Other Expenses AllOtherExpenses

Field	Value	IRS element (for citing)
Total	903390	Total
Program Services	418180	ProgramServices
Management And General	284959	ManagementAndGeneral
Fundraising	200251	Fundraising

Total Functional Expenses TotalFunctionalExpenses

Field	Value	IRS element (for citing)
Total	26110413	Total
Program Services	19695968	ProgramServices
Management And General	1975666	ManagementAndGeneral
Fundraising	4438779	Fundraising

Field	Value	IRS element (for citing)
Joint Costs	X	JointCosts

Total Joint Costs TotalJointCosts

Field	Value	IRS element (for citing)
Total	1018136	Total
Program Services	335788	ProgramServices
Fundraising	682348	Fundraising

Cash Non Interest Bearing CashNonInterestBearing

Field	Value	IRS element (for citing)
BOY	5446802	BOY
EOY	6837885	EOY

Savings And Temp Cash Investments SavingsAndTempCashInvestments

Field	Value	IRS element (for citing)
BOY	5963522	BOY
EOY	216839	EOY

Pledges And Grants Receivable PledgesAndGrantsReceivable

Field	Value	IRS element (for citing)
BOY	6860128	BOY
EOY	5793558	EOY

Accounts Receivable AccountsReceivable

Field	Value	IRS element (for citing)
BOY	2471863	BOY
EOY	2949128	EOY

Inventories For Sale Or Use InventoriesForSaleOrUse

Field	Value	IRS element (for citing)
BOY	144295	BOY
EOY	94865	EOY

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

Field	Value	IRS element (for citing)
BOY	513604	BOY
EOY	418292	EOY

Field	Value	IRS element (for citing)
Land Buildings Equipment Basis	3305513	LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec	2756566	LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

Field	Value	IRS element (for citing)
BOY	471557	BOY
EOY	548947	EOY

Investments Pub Traded Securities InvestmentsPubTradedSecurities

Field	Value	IRS element (for citing)
BOY	13623286	BOY
EOY	20785048	EOY

Other Assets Total OtherAssetsTotal

Field	Value	IRS element (for citing)
BOY	309373	BOY
EOY	359753	EOY

Total Assets TotalAssets

Field	Value	IRS element (for citing)
BOY	35804430	BOY
EOY	38004315	EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

Field	Value	IRS element (for citing)
BOY	1644227	BOY
EOY	1894675	EOY

Grants Payable GrantsPayable

Field	Value	IRS element (for citing)
BOY	573765	BOY
EOY	1394222	EOY

Deferred Revenue DeferredRevenue

Field	Value	IRS element (for citing)
BOY	2679898	BOY
EOY	3003684	EOY

Other Liabilities OtherLiabilities

Field	Value	IRS element (for citing)
BOY	340774	BOY
EOY	271653	EOY

Total Liabilities TotalLiabilities

Field	Value	IRS element (for citing)
BOY	5238664	BOY
EOY	6564234	EOY

Field	Value	IRS element (for citing)
Follow SFAS117	X	FollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	18976216	BOY
EOY	20620662	EOY

Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	11262381	BOY
EOY	10486272	EOY

Permanently Restricted Net Assets PermanentlyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	327169	BOY
EOY	333147	EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	30565766	BOY
EOY	31440081	EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	35804430	BOY
EOY	38004315	EOY

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	X	InfoInScheduleOPartXI
Reconcilation Revenue Expenses	1204547	ReconcilationRevenueExpenses
Reconcilation Other Changes	-330232	ReconcilationOtherChanges
Method Of Accounting Accrual	X	MethodOfAccountingAccrual
Accountant Compile Or Review	false	AccountantCompileOrReview
FS Audited	true	FSAudited
Audit Committee	true	AuditCommittee
Financial Statement Separate	X	FinancialStatementSeparate
Federal Grant Audit Required	true	FederalGrantAuditRequired
Federal Grant Audit Performed	true	FederalGrantAuditPerformed

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Publicly Supported Org170b1 Avi	X	PubliclySupportedOrg170b1Avi

Gifts Grants Contrib Received170 GiftsGrantsContribReceived170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	22038265	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	30491706	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	20760601	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	22553697	CurrentTaxYearMinus1Year
Current Tax Year	22876129	CurrentTaxYear
Total	118720398	Total

Total170 Total170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	22038265	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	30491706	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	20760601	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	22553697	CurrentTaxYearMinus1Year
Current Tax Year	22876129	CurrentTaxYear
Total	118720398	Total

Field	Value	IRS element (for citing)
Amounts Subst Contributors Total	5841089	AmountsSubstContributorsTotal
Public Support Total170	112879309	PublicSupportTotal170

Gross Investment Income170 GrossInvestmentIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	822092	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	842799	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	643473	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	668573	CurrentTaxYearMinus1Year
Current Tax Year	951963	CurrentTaxYear
Total	3928900	Total

Other Income170 OtherIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	20042	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	4177745	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	117005	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	2317760	CurrentTaxYearMinus1Year
Current Tax Year	1492968	CurrentTaxYear
Total	8125520	Total

Field	Value	IRS element (for citing)
Total Support	130774818	TotalSupport
Gross Receipts From Admissions Etc	203937	GrossReceiptsFromAdmissionsEtc
Public Support Pertcentage170	0.86316	PublicSupportPertcentage170
Public Support Pertcent Prior Year	0.84905	PublicSupportPertcentPriorYear
Thirty Three Percnt Tests CY170	X	ThirtyThreePercntTestsCY170

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

Field	Value	IRS element (for citing)
Contributor Number	RESTRICTED	ContributorNumber

Contributor Name Business ContributorNameBusiness

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor Address US ContributorAddressUS

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Aggregate Contributions	RESTRICTED	AggregateContributions

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Total Grassroots Lobbying		TotalGrassrootsLobbying
Total Direct Lobbying		TotalDirectLobbying
Total Lobbying Expenditures		TotalLobbyingExpenditures
Other Exempt Purpose Expenditures		OtherExemptPurposeExpenditures
Total Exempt Purpose Expenditures		TotalExemptPurposeExpenditures
Lobbying Nontaxable		LobbyingNontaxableAmount
Grassroots Nontaxable		GrassrootsNontaxableAmount
Tot Lobbying Grassroot Minus Non Tx		TotLobbyingGrassrootMinusNonTx
Tot Lobby Expend Mns Lobbying Nontx		TotLobbyExpendMnsLobbyingNontx
Volunteers	false	Volunteers
Paid Staff Or Management	true	PaidStaffOrManagement
Media Advertisements	false	MediaAdvertisements
Mailings Members	false	MailingsMembers
Publications Or Broadcast	false	PublicationsOrBroadcast
Grants Other Organizations	false	GrantsOtherOrganizations
Direct Contact Legislators	false	DirectContactLegislators
Rallies Demonstrations	false	RalliesDemonstrations
Other Activities	true	OtherActivities
Other Activities	$138,471	OtherActivitiesAmount
Total Lobbying Expenditures IIB	138471	TotalLobbyingExpendituresIIB
Not Described In501c3	false	NotDescribedIn501c3
Form4720 Filed4912 Tax	false	Form4720Filed4912Tax

Form990 Schedule C Part IV Form990ScheduleCPartIV

Field	Value	IRS element (for citing)
Identifier	Lobbying Expenses	Identifier
Return Reference	Part II-B	ReturnReference
Explanation	The Foundation for AIDS Research developed issue briefs on the potential impact of various budget scenarios for global health, new approaches to HIV prevention among gay men, the policy implications of scientific advances in AIDS, and other issues. These issue briefs were shared with Capitol Hill staff. AMFAR met regularly with staff to members of Congress and with Administration staff. AMFAR held briefings on Capitol Hill on how to "End the Epidemic," HIV prevention, and AIDS research. amfAR uses these briefings as an educational tool. AMFAR contracted with a consultant to encourage advocacy by constituents in key states on global AIDS funding.	Explanation

Schedule D IRS990ScheduleD

Art Public Exhibition Amts ArtPublicExhibitionAmts

Field	Value	IRS element (for citing)
Assets In Part X	94865	AssetsInPartX

Field	Value	IRS element (for citing)
Held Works Of Art Amts		HeldWorksOfArtAmts

Collection Used For Other CollectionUsedForOther

Field	Value	IRS element (for citing)
Collection Used For Other Purposes	X	CollectionUsedForOtherPurposes
Description Of Other Purposes	Donated Items, Inventory etc.	DescriptionOfOtherPurposes

Field	Value	IRS element (for citing)
Solicited Assets For Sale	true	SolicitedAssetsForSale

Current Year CurrentYear

Field	Value	IRS element (for citing)
Beginning Of Year Balance	561083	BeginningOfYearBalance
Contributions	5978	Contributions
Investment Earnings Or Losses	-2705	InvestmentEarningsOrLosses
Other Expenditures	100000	OtherExpenditures
End Of Year Balance	464356	EndOfYearBalance

Current Year Minus1 Year CurrentYearMinus1Year

Field	Value	IRS element (for citing)
Beginning Of Year Balance	516826	BeginningOfYearBalance
Contributions	8258	Contributions
Investment Earnings Or Losses	35999	InvestmentEarningsOrLosses
End Of Year Balance	561083	EndOfYearBalance

Current Year Minus2 Years CurrentYearMinus2Years

Field	Value	IRS element (for citing)
Beginning Of Year Balance	470065	BeginningOfYearBalance
Contributions	9378	Contributions
Investment Earnings Or Losses	37383	InvestmentEarningsOrLosses
End Of Year Balance	516826	EndOfYearBalance

Field	Value	IRS element (for citing)
Permanent Endowment EOY Balance	0.28260	PermanentEndowmentEOYBalance
Term Endowment EOY Balance	0.71740	TermEndowmentEOYBalance
Endowments Held By Unrelated Orgs	false	EndowmentsHeldByUnrelatedOrgs
Endowments Held By Related Orgs	false	EndowmentsHeldByRelatedOrgs
Land		Land
Buildings		Buildings

Leasehold Improvements LeaseholdImprovements

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	781297	OtherCostOrOtherBasis
Depreciation	743877	Depreciation
Book Value	37420	BookValue

Equipment Equipment

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	236509	OtherCostOrOtherBasis
Depreciation	233430	Depreciation
Book Value	3079	BookValue

Other Land Buildings OtherLandBuildings

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	2287707	OtherCostOrOtherBasis
Depreciation	1779259	Depreciation
Book Value	508448	BookValue

Field	Value	IRS element (for citing)
Total Of Book Value Land Buildings	548947	TotalOfBookValueLandBuildings
Federal Income Tax Liability	0	FederalIncomeTaxLiability

Other Liabilities OtherLiabilities

Field	Value	IRS element (for citing)
Description	MISCELLANEOUS	Description
Amount	$271,653	Amount

Field	Value	IRS element (for citing)
Total Of Amounts	271653	TotalOfAmounts
Total Revenue	27314960	TotalRevenue
Total Expenses	26110413	TotalExpenses
Excess Or Deficit For Year	1204547	ExcessOrDeficitForYear
Net Unrealized GL On Investments	-465956	NetUnrealizedGLOnInvestments
Other	$135,728	OtherAmount
Total Adjustments	-330228	TotalAdjustments
Excess Or Deficit Per FS	874319	ExcessOrDeficitPerFS
Tot Revenue Etc Audited Fincl Stmt	27165227	TotRevenueEtcAuditedFinclStmt
Net Unrealized Gains Investments	-465956	NetUnrealizedGainsInvestments
Donated Srvc And Use Of Facilities	316223	DonatedSrvcAndUseOfFacilities
Revenue Not Rptd F990	-149733	RevenueNotRptdF990
Revenue Subtotal	27314960	RevenueSubtotal
Total Revenue Per Form990	27314960	TotalRevenuePerForm990
Tot Expenses Etc Audited Fincl Stmt	26290908	TotExpensesEtcAuditedFinclStmt
Donated Services Use Of Facilities	180495	DonatedServicesUseOfFacilities
Expenses Not Rptd F990	180495	ExpensesNotRptdF990
Expenses Subtotal	26110413	ExpensesSubtotal
Total Expenses Per Form990	26110413	TotalExpensesPerForm990

Form990 Schedule D Part XIV Form990ScheduleDPartXIV (4 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
Endowments	Part V, Line 4	AMFAR's endowment fund is intended to fund the various general research programs the organization sponsors.
FIN 48	Income taxes	Amfar follows guidance that clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a tax return, including issues relating to financial statement recognition and guidance on measurement, classification, interest and penalties, and disclosure. As of September 30, 2011, amfar does not believe that there are any uncertain tax positions within its financial statements. Amfar has processes presently in place to ensure the maintenance of its tax-exempt status; to identify and report unrelated income; to determine its filing and tax obligations in jurisdictions for which it has nexus; and to identify and evaluate other matters that may be considered tax positions. The tax years ended 2008, 2009, and 2010 are still open to audit for both federal and state purposes.
reconciliation		part XI, Line 8 Value of Donated Services Capitalized Rather than Expenses - $135,728 (Please refer to Part XII, Line 2(b) and Part XIII, Line 2(a) for the difference in the reported amount of donated services).
Collections of Art, Histocial Treasures, or other similar assets	Part III, Line 4	AMFAR holds various items of jewelry, photographs and other items of artistic value that have been donated to the organization for sale at special events. The organization has maintained these items in inventory for a few years and is in the process of selling them.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	true	GrantRecordsMaintained

Accts Actvs Out US Table AcctsActvsOutUSTable (12 entries)

RegionRegion	Number Of OfficesNumberOfOffices	Number Of EmployeesNumberOfEmployees	Type Of Activities ConductedTypeOfActivitiesConducted	Specific Services ProvidedSpecificServicesProvided	Total ExpendituresTotalExpenditures
Central America and the Caribbean	0	0	Grantmaking	N/A	399614
East Asia and the Pacific	1	15	Program Services	Therapeutics Research	1249297
East Asia and the Pacific	1	15	Grantmaking	N/A	2759765
Europe (Including Iceland and Greenland)	0	0	Grantmaking	N/A	466145
Europe (Including Iceland and Greenland)	0	0	Fundraising	N/A	3032080
North America	0	0	Fundraising	N/A	272343
Russia and the Newly Independent States	0	0	Grantmaking	N/A	132018
South America	0	0	Fundraising	N/A	437282
South Asia	0	0	Grantmaking	N/A	93360
Sub-Saharan Africa	0	0	Grantmaking	N/A	184202
Middle East and North Africa	0	0	Grantmaking	N/A	19789
South America	0	0	Grantmaking	N/A	128964

Field	Value	IRS element (for citing)
Subtotal Number Of Offices	2	SubtotalNumberOfOffices
Subtotal Number Of Employees	30	SubtotalNumberOfEmployees
Total Number Of Offices	2	TotalNumberOfOffices
Total Number Of Employees	30	TotalNumberOfEmployees
Subtotal Amount Spent	9174859	SubtotalAmountSpent
Total Amount Spent	9174859	TotalAmountSpent

Grants To Orgs Outside US GrantsToOrgsOutsideUS (157 entries)

RegionRegion	Purpose Of GrantPurposeOfGrant	Amount Of Cash GrantAmountOfCashGrant	Manner Of Cash DisbursementMannerOfCashDisbursement
Cent. America/Caribbean	MSM INITIATIVES	20000	Wire Transfe
Cent. America/Caribbean	MSM INITIATIVES	20000	Wire Transfe
Cent. America/Caribbean	MSM INITIATIVES	20000	Wire Transfe
Cent. America/Caribbean	MSM INITIATIVES	19636	Wire Transfe
Cent. America/Caribbean	MSM INITIATIVES	19978	Wire Transfe
Cent. America/Caribbean	MSM INITIATIVES	10000	Wire Transfe
Cent. America/Caribbean	MSM INITIATIVES	10000	Wire Transfe
Cent. America/Caribbean	MSM INITIATIVES	20000	Wire Transfe
Cent. America/Caribbean	MSM INITIATIVES	10000	Wire Transfe
Cent. America/Caribbean	PREVENTION SCIENCE OUTREACH	250000	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	12375	Wire Transfe
East Asia/Pacific	TREAT ASIA	7501	Wire Transfe
East Asia/Pacific	TREAT ASIA	5710	Wire Transfe
East Asia/Pacific	BASIC RESEARCH	46875	Wire Transfe
East Asia/Pacific	BASIC RESEARCH	36456	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	50000	Wire Transfe
East Asia/Pacific	TREAT ASIA	20000	Wire Transfe
East Asia/Pacific	TREAT ASIA	12746	Wire Transfe
East Asia/Pacific	TREAT ASIA	21825	Wire Transfe
East Asia/Pacific	TREAT ASIA	12080	Wire Transfe
East Asia/Pacific	TREAT ASIA	15724	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	10874	Wire Transfe
East Asia/Pacific	TREAT ASIA	28954	Wire Transfe
East Asia/Pacific	TREAT ASIA	15724	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	11626	Wire Transfe
East Asia/Pacific	TREAT ASIA	52083	Wire Transfe
East Asia/Pacific	TREAT ASIA	329578	Wire Transfe
East Asia/Pacific	TREAT ASIA	159548	Wire Transfe
East Asia/Pacific	TREAT ASIA	143428	Wire Transfe
East Asia/Pacific	TREAT ASIA	31893	Wire Transfe
East Asia/Pacific	TREAT ASIA	14316	Wire Transfe
East Asia/Pacific	TREAT ASIA	100000	Wire Transfe
East Asia/Pacific	TREAT ASIA	116501	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	14589	Wire Transfe
East Asia/Pacific	TREAT ASIA	14999	Wire Transfe
East Asia/Pacific	TREAT ASIA	37499	Wire Transfe
East Asia/Pacific	TREAT ASIA	9000	Wire Transfe
East Asia/Pacific	TREAT ASIA	11250	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	7500	Wire Transfe
East Asia/Pacific	TREAT ASIA	6000	Wire Transfe
East Asia/Pacific	TREAT ASIA	16350	Wire Transfe
East Asia/Pacific	TREAT ASIA	14999	Wire Transfe
East Asia/Pacific	TREAT ASIA	24374	Wire Transfe
East Asia/Pacific	TREAT ASIA	16350	Wire Transfe
East Asia/Pacific	TREAT ASIA	21375	Wire Transfe
East Asia/Pacific	TREAT ASIA	8400	Wire Transfe
East Asia/Pacific	TREAT ASIA	14950	Wire Transfe
East Asia/Pacific	TREAT ASIA	5625	Wire Transfe
East Asia/Pacific	TREAT ASIA	33054	Wire Transfe
East Asia/Pacific	TREAT ASIA	7500	Wire Transfe
East Asia/Pacific	TREAT ASIA	5625	Wire Transfe
East Asia/Pacific	TREAT ASIA	10000	Wire Transfe
East Asia/Pacific	TREAT ASIA	12080	Wire Transfe
East Asia/Pacific	TREAT ASIA	5625	Wire Transfe
East Asia/Pacific	TREAT ASIA	16126	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	11250	Wire Transfe
East Asia/Pacific	TREAT ASIA	7333	Wire Transfe
East Asia/Pacific	TREAT ASIA	5550	Wire Transfe
East Asia/Pacific	TREAT ASIA	7500	Wire Transfe
East Asia/Pacific	TREAT ASIA	5625	Wire Transfe
East Asia/Pacific	TREAT ASIA	9398	Wire Transfe
East Asia/Pacific	TREAT ASIA	7125	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	26430	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	6375	Wire Transfe
East Asia/Pacific	TREAT ASIA	11250	Wire Transfe
East Asia/Pacific	TREAT ASIA	7501	Wire Transfe
East Asia/Pacific	TREAT ASIA	5271	Wire Transfe
East Asia/Pacific	TREAT ASIA	14625	Wire Transfe
East Asia/Pacific	TREAT ASIA	7200	Wire Transfe
East Asia/Pacific	TREAT ASIA	16350	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	20626	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	34138	Wire Transfe
East Asia/Pacific	TREAT ASIA	30000	Wire Transfe
East Asia/Pacific	TREAT ASIA	6300	Wire Transfe
East Asia/Pacific	TREAT ASIA	6525	Wire Transfe
East Asia/Pacific	TREAT ASIA	10000	Wire Transfe
East Asia/Pacific	TREAT ASIA	20550	Wire Transfe
East Asia/Pacific	TREAT ASIA	20626	Wire Transfe
East Asia/Pacific	TREAT ASIA	21800	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	11250	Wire Transfe
East Asia/Pacific	TREAT ASIA	92000	Wire Transfe
East Asia/Pacific	TREAT ASIA	7501	Wire Transfe
East Asia/Pacific	TREAT ASIA	20000	Wire Transfe
East Asia/Pacific	TREAT ASIA	131202	Wire Transfe
East Asia/Pacific	TREAT ASIA	60992	Wire Transfe
East Asia/Pacific	TREAT ASIA	5900	Wire Transfe
East Asia/Pacific	TREAT ASIA	11626	Wire Transfe
East Asia/Pacific	TREAT ASIA	10103	Wire Transfe
East Asia/Pacific	TREAT ASIA	27195	Wire Transfe
East Asia/Pacific	MSM INITIATIVE	19900	Wire Transfe
East Asia/Pacific	TREAT ASIA	38715	Wire Transfe
East Asia/Pacific	TREAT ASIA	43482	Wire Transfe
East Asia/Pacific	TREAT ASIA	6000	Wire Transfe
East Asia/Pacific	MSM INITIATIVE	20000	Wire Transfe
East Asia/Pacific	MSM INITIATIVE	20000	Wire Transfe
East Asia/Pacific	MSM INITIATIVE	19963	Wire Transfe
East Asia/Pacific	MSM INITIATIVE	16700	Wire Transfe
East Asia/Pacific	MSM INITIATIVE	20000	Wire Transfe
East Asia/Pacific	MSM INITIATIVE	18600	Wire Transfe
East Asia/Pacific	MSM INITIATIVE	15000	Wire Transfe
East Asia/Pacific	MSM INITIATIVE	19700	Wire Transfe
East Asia/Pacific	TREAT ASIA	15000	Wire Transfe
East Asia/Pacific	TREAT ASIA	19950	Wire Transfe
Europe/Iceland/Greenland	BASIC RESEARCH	5223	Wire Transfe
Europe/Iceland/Greenland	BASIC RESEARCH	15626	Wire Transfe
Europe/Iceland/Greenland	BASIC RESEARCH	70000	Wire Transfe
Europe/Iceland/Greenland	BASIC RESEARCH	26640	Wire Transfe
Europe/Iceland/Greenland	MSM INITIATIVE	18000	Wire Transfe
Europe/Iceland/Greenland	BASIC RESEARCH	210000	Wire Transfe
Europe/Iceland/Greenland	BASIC RESEARCH	36456	Wire Transfe
Europe/Iceland/Greenland	BASIC RESEARCH	90000	Wire Transfe
Middle East/North Africa	MSM INITIATIVE	19789	Wire Transfe
Russia	MSM INITIATIVE	20000	Wire Transfe
Russia	MSM INITIATIVE	18000	Wire Transfe
Russia	MSM INITIATIVE	19891	Wire Transfe
Russia	MSM INITIATIVE	9500	Wire Transfe
Russia	MSM INITIATIVE	10364	Wire Transfe
Russia	MSM INITIATIVE	19861	Wire Transfe
Russia	MSM INITIATIVE	16680	Wire Transfe
Russia	MSM INITIATIVE	17722	Wire Transfe
South America	MSM INITIATIVE	19790	Wire Transfe
South America	MSM INITIATIVE	20000	Wire Transfe
South America	MSM INITIATIVE	19975	Wire Transfe
South America	MSM INITIATIVE	19976	Wire Transfe
South America	MSM INITIATIVE	20000	Wire Transfe
South America	MSM INITIATIVE	19260	Wire Transfe
South America	MSM INITIATIVE	9963	Wire Transfe
South Asia	treat asia	15000	Wire Transfe
South Asia	treat asia	15000	Wire Transfe
South Asia	treat asia	5625	Wire Transfe
South Asia	treat asia	8662	Wire Transfe
South Asia	MSM INITIATIVE	20000	Wire Transfe
South Asia	MSM INITIATIVE	19148	Wire Transfe
Sub-Saharan Africa	BASIC RESEARCH	14264	Wire Transfe
Sub-Saharan Africa	MSM INITIATIVE	20000	Wire Transfe
Sub-Saharan Africa	PUBLIC POLICY	20000	Wire Transfe
Sub-Saharan Africa	MSM INITIATIVE	20000	Wire Transfe
Sub-Saharan Africa	MSM INITIATIVE	20000	Wire Transfe
Sub-Saharan Africa	MSM INITIATIVE	20000	Wire Transfe
Sub-Saharan Africa	MSM INITIATIVE	20000	Wire Transfe
Sub-Saharan Africa	MSM INITIATIVE	20000	Wire Transfe
Sub-Saharan Africa	MSM INITIATIVE	10000	Wire Transfe
Sub-Saharan Africa	PUBLIC POLICY	20000	Wire Transfe
Sub-Saharan Africa	MSM INITIATIVE	20000	Wire Transfe

Field	Value	IRS element (for citing)
Total Number Of501c3 Orgs	157	TotalNumberOf501c3Orgs
Total Number Of Other Orgs	0	TotalNumberOfOtherOrgs
Transfer To Foreign Corp	false	TransferToForeignCorp
Interest In Foreign Trust	false	InterestInForeignTrust
Own Foreign Corp	false	OwnForeignCorp
Passive Foreign Invest Co	false	PassiveForeignInvestCo
Foreign Partnership	false	ForeignPartnership
Boycott Countries	false	BoycottCountries

Form990 Schedule F Part V Form990ScheduleFPartV (3 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
Foreign Activities	Part I, Line 2	International organizations are recommended for funding based upon the results of community-based peer review and/or program staff assessment of proposal merit and organization capacity to undertake proposed projects that are CHARITABLE in purpose. Pre-award due-diligence for new international grantees includes review of organization documents and registrations to verify that the organization operates for a CHARITABLE purpose and that basic capacity for project oversight and governance has been established. All international grantees are required to report semi-annually on project progress and expenditures; continued reporting is required until such time as grant funds are expended in full. Reports are reviewed by administrative and program staff. Additional oversight is provided as necessary by means of ongoing, informal contact with sites regarding progress and technical issues and site visits where feasible. International research grant recipients submit an interim and a final progress reporting addition to expenditures reports due following the ends of the 2nd, 3rd and final quarters of the performance period.
foreign activities	Part I, Line 3, Column D	The Foundation for AIDS Research conducts many of its grant-making program services (see Part III of Form 990) in U.S. and foreign jurisdictions. In column D, the organization has reported the basic program these grants support; please refer to Part III for more information about these programs/initiatives.
Foreign Activities - Status of Grantees		The Foundation for Aids Research supports many non-U.S. organizations in the fight against AIDS and HIV-related diseases. For purposes of Schedule F, Part II, Line 2 - all 157 charities supported are presumed to be the equivalent of U.S. charities.

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	X	MailSolicitations
Email Solicitations	X	EmailSolicitations
Phone Solicitations	X	PhoneSolicitations
Solicitation Of Non Govt Grants	X	SolicitationOfNonGovtGrants
Solicitation Of Govt Grants	X	SolicitationOfGovtGrants
Special Fundraising Events	X	SpecialFundraisingEvents
Agreement Ref Fundraising	true	AgreementRefFundraising

Fundraiser Activity Information FundraiserActivityInformation (5 entries)

Name Of IndividualNameOfIndividual	ActivityActivity	Fundraiser Control Of FundsFundraiserControlOfFunds	Gross ReceiptsGrossReceipts	Amount Retained By ContractorAmountRetainedByContractor	Net To OrganizationNetToOrganization
aab productions	Fundraising Event/Prod	false	11113567	222400	10891167
john mini consulting inc	direct mail	false	2108612	120500	1988112
public interest communications	tele marketing	false	38269	51679	-13410
sgr consulting	event production	false	333385	70500	262885
telefund	tele marketing	false	142199	85634	56565

Field	Value	IRS element (for citing)
Total Gross Receipts	13736032	TotalGrossReceipts
Total Retained By Contractors	550713	TotalRetainedByContractors
Total Net To Organization	13185319	TotalNetToOrganization
Licensed States	AL	LicensedStates
Licensed States	AK	LicensedStates
Licensed States	AZ	LicensedStates
Licensed States	AR	LicensedStates
Licensed States	CA	LicensedStates
Licensed States	CO	LicensedStates
Licensed States	CT	LicensedStates
Licensed States	DC	LicensedStates
Licensed States	FL	LicensedStates
Licensed States	GA	LicensedStates
Licensed States	HI	LicensedStates
Licensed States	IL	LicensedStates
Licensed States	KS	LicensedStates
Licensed States	KY	LicensedStates
Licensed States	LA	LicensedStates
Licensed States	ME	LicensedStates
Licensed States	MD	LicensedStates
Licensed States	MI	LicensedStates
Licensed States	MN	LicensedStates
Licensed States	MS	LicensedStates
Licensed States	MO	LicensedStates
Licensed States	MT	LicensedStates
Licensed States	NH	LicensedStates
Licensed States	NJ	LicensedStates
Licensed States	NM	LicensedStates
Licensed States	NY	LicensedStates
Licensed States	NC	LicensedStates
Licensed States	ND	LicensedStates
Licensed States	OH	LicensedStates
Licensed States	OK	LicensedStates
Licensed States	OR	LicensedStates
Licensed States	PA	LicensedStates
Licensed States	RI	LicensedStates
Licensed States	SC	LicensedStates
Licensed States	TN	LicensedStates
Licensed States	TX	LicensedStates
Licensed States	UT	LicensedStates
Licensed States	VA	LicensedStates
Licensed States	WA	LicensedStates
Licensed States	WV	LicensedStates
Licensed States	WI	LicensedStates

Events Information EventsInformation

Field	Value	IRS element (for citing)
Name Of Event1	CANNES EVENT	NameOfEvent1
Gross Receipts Event1	8886797	GrossReceiptsEvent1
Charitable Contributions Event1	8474297	CharitableContributionsEvent1
Gross Revenue Event1	412500	GrossRevenueEvent1
Rent Facility Costs Event1	544532	RentFacilityCostsEvent1
Other Direct Expenses Event1	1834820	OtherDirectExpensesEvent1
Name Of Event2	DALLAS EVENT	NameOfEvent2
Gross Receipts Event2	4223695	GrossReceiptsEvent2
Charitable Contributions Event2	4132495	CharitableContributionsEvent2
Gross Revenue Event2	91200	GrossRevenueEvent2
Rent Facility Costs Event2	46803	RentFacilityCostsEvent2
Other Direct Expenses Event2	2334363	OtherDirectExpensesEvent2
Total Number Of Other Events	10	TotalNumberOfOtherEvents
Gross Receipts Other Events	5937265	GrossReceiptsOtherEvents
Charitable Contrib Other Events	4988135	CharitableContribOtherEvents
Gross Revenue Other Events	949130	GrossRevenueOtherEvents
Rent Facility Costs Other Events	151155	RentFacilityCostsOtherEvents
Other Direct Expenses Other Events	2291931	OtherDirectExpensesOtherEvents
Gross Receipts Total	19047757	GrossReceiptsTotal
Charitable Contributions Total	17594927	CharitableContributionsTotal
Gross Revenue Total Events	1452830	GrossRevenueTotalEvents
Rent Facility Costs Total Events	742490	RentFacilityCostsTotalEvents
Other Direct Expenses Total Events	6461114	OtherDirectExpensesTotalEvents
Direct Expense Summary Events	7203604	DirectExpenseSummaryEvents
Net Income Summary	-5750774	NetIncomeSummary

Form990 Schedule G Part IV Form990ScheduleGPartIV

Field	Value	IRS element (for citing)
Identifier	Schedule G, Part I	Identifier
Explanation	The Foundation for AIDS Research actually paid out $403,803 in fundraising expenses for the year ending September 30, 2011. This amount is reported on Part IX, Line 11(e). For purposes of Schedule G, the Foundation is reporting all amounts paid to the consultants listed on Part I, regardless of whether such amounts were pure fundraising expenses or event production costs. On Schedule G, the total amount paid to the organizations listed is $550,713. Of that $550,713, only $403,813 was paid for fundraising services, the remaining $146,900 was paid for event production services.	Explanation

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Records Maintained	true	RecordsMaintained

Recipient Table RecipientTable (41 entries)

Address Line1AddressUS/AddressLine1	CityAddressUS/City	StateAddressUS/State	ZIP CodeAddressUS/ZIPCode	EIN Of RecipientEINOfRecipient	IRC SectionIRCSection	Amount Of Cash GrantAmountOfCashGrant	Purpose Of GrantPurposeOfGrant
University of Utah
75 S 2000 E Second Fl	Salt Lake City	UT	84112	187600525	501(c)(3)	15626	basic research
Dana-Farber Cancer Institute Harvard Medical Sch
44 Binney St	Boston	MA	02115	042263040	501(c)(3)	15626	Basic Research
University of Utah
75 S 2000 E Second Fl	Salt Lake City	UT	84112	187600525	501(c)(3)	31251	Basic Research
Yale University School of Medicine
47 College Street	New Haven	CT	06520	060646973	501(c)(3)	15626	Basic Research
Weill Medical College of Cornell Univ
1300 York Avenue	New York	NY	10065	131623978	501(c)(3)	62502	Basic Research
UT Southwestern Medical Center
5323 Harry Hines Blvd	Dallas	TX	753909105	175600286	501(c)(3)	62502	Basic Research
NYU School of Medicine
550 First Avenue	New York	NY	10016	113556230	501(c)(3)	36460	Basic Research
University of California-Davis
One Shields Avenue	Davis	CA	95616	946036494	501(c)(3)	62501	Basic Research
California Institute of Technology
1200 East California Blvd	Pasadena	CA	91106	951643307	501(c)(3)	62501	Biomedical Cure Research
University of Minnesota
200 Oak Street SE	Minneapolis	MN	554552070	416007513	501(c)(3)	62501	Basic Research
University of Florida
1600 SW Archer Rd ARB R1-252	Gainesville	FL	32610	592729133	501(c)(3)	50000	Basic Research
University of WashingtonFHCRC
1100 Fairview Avenue N D3-100	Seattle	WA	98109	916001537	501(c)(3)	40000	Basic Research
University of Texas Southwestern
5323 Harry Hines Blvd L4256	Dallas	TX	75390	175600286	501(c)(3)	20000	Basic Research
Albert Einstein College of Medicine
1300 Morris Park Avenue	Bronx	NY	10461	132937352	501(c)(3)	33333	Basic Research
The Regents of the Univ of California SF
333 California Street Suite 315	San Francisco	CA	94110	946036493	501(c)(3)	210000	Basic Research
Johns Hopkins University
733 N Broadway 117 Broadway Res	Baltimore	MD	21205	520595110	501(c)(3)	210000	Biomedical Cure Research
Beckman Research Institue of City of Hope
1500 E Duarte Road	Duarte	CA	910103000	953432210	501(c)(3)	70000	Biomedical Cure Research
NYU School of Medicine
550 First Avenue	New York	NY	10016	113556230	501(c)(3)	21999	Social/Behavioral Research
Montefiore Medical Center
111 E 210th St	Bronx	NY	10467	131740114	501(c)(3)	22000	Policy Research
Dana-Farber Cancer Institute Inc
44 Binney St	Boston	MA	02115	042263040	501(c)(3)	46875	Basic Research
University of Wisconsin-Madison
21 North Park Street Suite 6401	Madison	WI	53715	396006492	501(c)(3)	46875	Basic Research
The Aaron Diamond AIDS Research Center
455 First Avenue 7th Floor	New York	NY	10016	133540234	501(c)(3)	46875	Basic Research
VGTI-Florida
11350 SW Village Parkway	Port St Lucie	FL	34987	364618350	501(c)(3)	70000	Biomedical Cure Research
University of California Los Angeles
11000 Kinross Avenue Suite 102	Los Angeles	CA	900951406	956006143	501(c)(3)	70000	Basic Research
University of Utah
15 North Medical Dr East 2100 25	Salt lake City	UT	84112	876000525	501(c)(3)	69972	Basic Research
University of Alabama at Birmingham
1530 Third Avenue South AB 1170	Birmingham	AL	352940111	163600539	501(c)(3)	50000	Biomedical Cure Research
George Mason University
10900 Univ Blvd Discovery Hall Ro	Manassas	VA	20110	540836354	501(c)(3)	58460	Basic Research
William J Clinton Foundation
1200 President Clinton Avenue	Little Rock	AR	72201	311580204	501(c)(3)	111000	Operations support for HIV/AIDS programs
Stanford University
301 Ravenswood Avenue	Menlo Park	CA	94025	941156365	501(c)(3)	96782	Basic Research
William J Clinton Foundation
1200 President Clinton Avenue	Little Rock	AR	72201	311580204	501(c)(3)	67339	Operations support for HIV/AIDS programs
Heartland Alliance for Human Needs and Rights
208 South LaSalle Street Suite 181	Chicago	IL	60604	361877640	501(c)(3)	10500	Direct Service/intervention
William J Clinton Foundation
1200 President Clinton Avenue	Little Rock	AR	77201	311580204	501(c)(3)	75000	Operations support for HIV/AIDS programs
Beth Israel Medical Center - Edmond de Rothschild
First Avenue at 18th Street	New York	NY	10003	135564934	501(c)(3)	75000	Policy Research
Johns Hopkins University
733 N Broadway	Baltimore	MD	21205	520595110	501(c)(3)	55999	Biomedical Cure Research
University of California San Francisco
333 California Street Suite 315	San Francisco	CA	94118	946036493	501(c)(3)	90000	Biomedical Cure Research
Trustees of the University of Pennsylvania
3451 Walnut Street Room P 221	Philadelphia	PA	19104	231352685	501(c)(3)	40000	Biomedical Cure Research
Johns Hopkins University
733 N Broadway 117 Broadway Res	Baltimore	MD	21205	520595110	501(c)(3)	90000	Biomedical Cure Research
Project Inform
1375 Mission Street	San Francisco	CA	94103	943052723	501(c)(3)	10000	Research/Conference Support
Case Western Reserve University
10900 Euclid Avenue	Cleveland	OH	44106	341018992	501(c)(3)	39600	Biomedical Cure Research
Johns Hopkins University
Room 117 Broadway Research Buildin	Baltimore	MD	21205	520595110	501(c)(3)	319147	Biomedical Cure Research
Johns Hopkins University Bloomberg School of Publi
615 N Wolfe Street	Baltimore	MD	21205	520595110	501(c)(3)	75000	Policy Research

Field	Value	IRS element (for citing)
Total Nbr Of501 C3 And Govt Grants	41	TotalNbrOf501C3AndGovtGrants
Total Nbr Of Other Organizations	0	TotalNbrOfOtherOrganizations

Form990 Schedule I Part IV Form990ScheduleIPartIV

Field	Value	IRS element (for citing)
Identifier	Grants and Assistance	Identifier
Return Reference	Part I, Line 2	ReturnReference
Explanation	All U.S. 501(c)(3) grant and award recipients are required to report at least once on activities supported with amfAR funds; all U.S. research grant recipients (which include 501(c)(3) organizations and other nonprofit entities such as state universities) are required to submit an interim and a final progress report in addition to expenditure reports due following the ends of the 2nd, 3rd and final quarters of the performance periods. Reports are reviewed by grant administration and program staff prior to payment and/or closeout.	Explanation

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	X	CompensationCommittee
Independent Consultant	X	IndependentConsultant
Written Employment Contract	X	WrittenEmploymentContract
Compensation Survey	X	CompensationSurvey
Board Or Committee Approval	X	BoardOrCommitteeApproval
Severance Payment	true	SeverancePayment
Supplemental Nonqual Retire Plan	true	SupplementalNonqualRetirePlan
Equity Based Comp Arrangement	false	EquityBasedCompArrangement
Comp Based On Revenue Of Filing Org	false	CompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related Orgs	false	CompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing Org	false	CompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate Orgs	false	CompBasedNetEarningsRelateOrgs
Any Non Fixed Payments	false	AnyNonFixedPayments
Initial Contract Exception	false	InitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (10 entries)

Base Compensation Filing OrgBaseCompensationFilingOrg	Comp Based On Related OrgsCompBasedOnRelatedOrgs	Bonus Filing OrgBonusFilingOrg	Bonus Related OrgsBonusRelatedOrgs	Other Compensation Filing OrgOtherCompensationFilingOrg	Other Compensation Related OrgsOtherCompensationRelatedOrgs	Deferred Comp Filing OrgDeferredCompFilingOrg	Deferred Comp Related OrgsDeferredCompRelatedOrgs	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrg	Nontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgs	Total Compensation Filing OrgTotalCompensationFilingOrg	Total Compensation Related OrgsTotalCompensationRelatedOrgs	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrg	Comp Report Prior990 Related OrgsCompReportPrior990RelatedOrgs
Kevin Frost
343450	0	0	0	0	0	27150	0	17352	0	387952	0	0	0
Bradley Jensen
191604	0	0	0	0	0	14303	0	25361	0	231268	0	0	0
John F Logan JD PhD
179618	0	0	0	0	0	13122	0	8254	0	200994	0	0	0
Rowena Johnston
145204	0	0	0	0	0	10236	0	8254	0	163694	0	0	0
Gregory L Boroff
207364	0	0	0	0	0	14921	0	8254	0	230539	0	0	0
Christopher Collins
165536	0	0	0	0	0	10973	0	25361	0	201870	0	0	0
Annette Sohn
172673	0	0	0	0	0	12078	0	3771	0	188522	0	0	0
Eric Muscatell
146674	0	0	0	0	0	10426	0	8254	0	165354	0	0	0
Andrew McInnes
123252	0	0	0	0	0	9043	0	25361	0	157656	0	0	0
Anthony Ancona
143131	0	0	0	0	0	10110	0	131	0	153372	0	0	0

Form990 Schedule J Part III Form990ScheduleJPartIII

Field	Value	IRS element (for citing)
Identifier	Compensation	Identifier
Return Reference	Part I, Line 4	ReturnReference
Explanation	Chief Executive Officer, Kevin Frost, participated in a supplemental nonqualified retirement plan; however, he did not receive a distribution in 2010.	Explanation

Schedule M IRS990ScheduleM

Field	Value	IRS element (for citing)
Works Of Art		WorksOfArt
Art Historical Treasures		ArtHistoricalTreasures
Art Fractional Interest		ArtFractionalInterest
Books And Publications		BooksAndPublications
Clothing And Household Goods		ClothingAndHouseholdGoods
Cars And Other Vehicles		CarsAndOtherVehicles
Boats And Planes		BoatsAndPlanes
Intellectual Property		IntellectualProperty

Securities Publicly Traded SecuritiesPubliclyTraded

Field	Value	IRS element (for citing)
Non Cash Checkbox	X	NonCashCheckbox
Number Of Contributions	11	NumberOfContributions
Noncash Contribs Rptd F990	18387	NoncashContribsRptdF990
Method Of Determining Revenues	sales price	MethodOfDeterminingRevenues

Field	Value	IRS element (for citing)
Securities Closely Held Stock		SecuritiesCloselyHeldStock
Securities Prtnrshp Trust Intrsts		SecuritiesPrtnrshpTrustIntrsts
Securities Miscellaneous		SecuritiesMiscellaneous
Qualified Contrib Hist Struct		QualifiedContribHistStruct
Qualified Contrib Other		QualifiedContribOther
Real Estate Residential		RealEstateResidential
Real Estate Commercial		RealEstateCommercial
Real Estate Other		RealEstateOther
Collectibles		Collectibles
Food Inventory		FoodInventory
Drugs And Medical Supplies		DrugsAndMedicalSupplies
Taxidermy		Taxidermy
Historical Artifacts		HistoricalArtifacts
Scientific Specimens		ScientificSpecimens
Archaeological Artifacts		ArchaeologicalArtifacts

Other Non Cash Contributions Table OtherNonCashContributionsTable (2 entries)

Non Cash CheckboxNonCashCheckbox	DescriptionDescription	Number Of ContributionsNumberOfContributions	Noncash Contribs Rptd F990NoncashContribsRptdF990	Method Of Determining RevenuesMethodOfDeterminingRevenues
X	Computers	1	135727	Fair Market Value
X	Airline Tickets	1	108402	Fair Market Value

Field	Value	IRS element (for citing)
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeld
Review Process Unusual NC Gifts	false	ReviewProcessUnusualNCGifts
Third Parties Used	true	ThirdPartiesUsed

Form990 Schedule M Part II Form990ScheduleMPartII

Field	Value	IRS element (for citing)
Identifier	Form 990, Schedule M, line 32a	Identifier
Explanation	To the extent that the organization receives contributions of securities, it uses its investment broker to liquidate those holdings to fund amfar's various research program activities.	Explanation

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (10 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
Program Service Accomplishments(1)	Part III, Line 4a-4d(1)	Line 4a: Research: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. amfAR fellowships allow talented young investigators to conduct original investigations under the guidance of experienced scientists, helping to ensure the long-term vitality of AIDS research. New Grants and Fellowships Grants and fellowships are awarded through a rigorous process of peer review by a team of independent HIV/AIDS experts drawn largely from the volunteer scientists on amfAR's Scientific Advisory Committee. Guided by its scientific advisors and with the approval of its board of trustees, amfAR pursues a strategic research plan that focuses on the treatment, prevention, and cure of HIV/AIDS. In 2011, amfAR awarded 22 new grants and fellowships totaling $3,040,608. Four researchers received Mathilde Krim Fellowships in Basic Biomedical Research, an initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The initiative has already achieved spectacular results, including numerous published studies in major scientific journals. The 2011 Krim Fellows-each of whom received $125,000-are working on new ways to treat HIV/AIDS and its associated conditions, as well as an HIV vaccine. Among the 2011 fellows is Nicholas Maness, Ph.D., of the University of Wisconsin-Madison, whose aim is to discover new proteins to act as targets for an HIV vaccine. All of the standard methods for making a vaccine, and even new ones not previously tried for any other disease; have so far failed to generate a product that can reduce the risk of HIV infection. Vaccines normally work by inducing immune responses against proteins associated with the virus they are intended to block. Dr. Maness believes there are previously undiscovered HIV proteins, and that the virus also makes proteins in a backwards (technically known as antisense) orientation. He will test for the presence and function of such novel HIV proteins to determine whether they may serve as the basis for a vaccine. Placing the search for a cure for HIV/AIDS at the center of its research efforts, the Foundation launched the amfAR Research Consortium on HIV Eradication (ARCHE) in 2010. Building on momentum from its first round of cure-focused grants issued last year, amfAR announced a second round of grants in 2011 to enable some teams to continue their groundbreaking research while adding two additional, promising projects aimed at unlocking more information about how to potentially eradicate HIV infection.
Program Service Accomplishments(2)	Part III, Line 4a-4d (2)	Line 4a, Continued - The second round of funding, totaling $1,042,000 went to five collaborative teams of researchers working in three areas considered central to HIV eradication: the search for a sterilizing cure to eliminate HIV from the body; the search for a functional cure to suppress the virus without treatment; and the characterization of viral reservoirs, which present an obstacle to a cure. Dr. Adriana Andrade of Johns Hopkins University, new to the ARCHE consortium, is testing the ability of disulfiram-a drug approved by the US Food and Drug Administration to treat alcoholism-to drive the virus out of infected cells in a small clinical study. Dr. Bob Siliciano, during his first year of ARCHE funding, identified and characterized the drug as an agent that might flush virus out of latently HIV-infected cells. Collaborating with Dr. Janice Clements, also of Johns Hopkins, he is investigating other FDA-approved drugs for their effect on latent HIV during his second year of funding. Also among this year's ARCHE grantees, Dr. Mike McCune of the University of California, San Francisco, collaborating with Dr. Steven Deeks, is examining the role of ongoing activation of the immune system-long suspected of playing a role in HIV disease-in the ability of HIV to persist during the lifetime of an infected patient. They will also test an FDA-approved drug that could play an integral role in a potential new therapeutic strategy that could bring us closer to a functional cure. Collaborating with the ARCHE investigators at UCSF, including Drs. Steven Deeks and Frederick Hecht, second-time ARCHE grantee Dr. Sarah Palmer of the Swedish Institute for Infectious Disease Control and Karolinska Institute continues to investigate which cellular reservoirs are most responsible for the persistence of HIV. These findings will inform efforts by the Siliciano/Clements and McCune/Deeks ARCHE groups by identifying the important targets of their efforts to purge reservoirs of virus or to modulate immune activation to effect a cure. The other new ARCHE grantee, Dr. Una O'Doherty of the University of Pennsylvania, is comparing methods for measuring HIV reservoir size to determine which are the most accurate and practical. The persistent reservoir of virus constitutes a tiny fraction of all virus present, but understanding how to measure changing levels of virus in the reservoir is difficult-and crucial to determining the next steps in HIV eradication. Published Research Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In the past year, at least 34 scientific publications resulted from amfAR-funded research. These covered current and past targeted areas of research interest. In the Lab, Recreating HIV's Hidden Reservoirs One major obstacle to curing HIV is the persistence in tissues of latent virus that is resistant to attack by current antiretroviral therapy (ART). Recent studies-including several published by amfAR grantees-have documented encouraging progress in the search for the reservoirs where virus persists. But even after zeroing in on HIV's hiding places, scientists need simple, clinically relevant test-tube models for testing new means of attacking the virus in these reservoirs. Dr. Alberto Bosque, one of amfAR's 2009 Mathilde Krim Fellows in Basic Biomedical Research, has helped to develop one such system. Writing in the January issue of the research journal Methods, Bosque and his mentor, Dr. Vicente Planelles, of the University of Utah, reviewed problems with older models of HIV latency. The authors concluded that no single test-tube or animal model for HIV latency is likely to capture the broad spectrum of means by which HIV hides or becomes activated. But their new system brings us one step closer to defining critical factors involved in maintaining latent HIV, with the ultimate aim of rationally designing drugs to destroy such viruses. An Animal Model for a Functional Cure for AIDS Writing in the August issue of PLoS Pathogens, a prestigious online journal, amfAR grantee Dr. Cristian Apetrei and colleagues described a functional cure of SIV, the simian counterpart of HIV, in rhesus monkeys. A functional cure controls the virus at extremely low levels in the body while a sterilizing cure entirely eliminates the virus from the body. Several critical pieces of the HIV disease puzzle have been addressed by their study. First, it shows that the immune system, through the CD8+ "killer" T cell, contributes to the control of an HIV-like infection. Second, it suggests that the chronic immune activation characteristic of HIV infection, even in those patients whose virus is seemingly well-controlled with drugs, is the result of incomplete suppression of virus. And unless such low levels of continuous virus growth can be blocked, it may preclude restoration of normal immunity. As Apetrei and associates appropriately concluded, their model provides the opportunity for further investigation into the phenomenon of "super-elites," which should enable "design of new approaches for controlling HIV infection" and help make a functional cure a reality. The Ethics of Universal HIV Screening Seeking to encourage earlier and more widespread HIV testing, in 2006 the U.S. Centers for Disease Control and Prevention (CDC) recommended an "opt-out" approach to testing, whereby healthcare workers would inform patients that they would be tested unless they declined. The aim of the new guidelines was to expand the number of HIV infections being diagnosed-considered a key to slowing the spread of the virus-and to get people into treatment earlier, thereby reducing the level of virus in their bodies and rendering them less infectious to others. Yet few national professional organizations have endorsed this recommendation. amfAR-supported researcher Dr. Roland Merchant of Brown University, writing in the American Journal of Bioethics, addresses the ethical concerns surrounding such testing. Merchant and colleagues concluded that if properly implemented, the CDC recommendations on universal testing could benefit both individuals and society. They emphasized that patients must be informed clearly that testing will take place, provided with informational materials about HIV and HIV testing, and told that they have the right to refuse testing. If the new HIV testing recommendations are otherwise ethically acceptable, their adoption should require only these sorts of safeguards to assure they are properly implemented. New Targeted RFP amfAR issued a request for proposals (RFP) in September 2011 for biomedical research projects relevant to exploring the mechanisms for HIV persistence and the potential for HIV eradication. Think Tanks and Conferences In April 2011, amfAR co-sponsored a think tank in Baltimore that brought together more than 50 leading academic researchers, government scientists, regulators, and community advocates to identify steps that can be taken to hasten the progress of cure-related research. And in July, amfAR Vice President and Director of Research Dr. Rowena Johnston co-chaired-with Nobel Prize winning scientist Dr. Franoise Barr-Sinoussi-"Controversies in HIV Cure Research," a panel discussion held in conjunction with the International AIDS Society conference in Rome.
Program Service Accomplishments (3)	Part III, Line 4a-4d (3)	Line 4b: TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 22 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. Eight papers based on the network's research were published in U.S. and international scientific journals in 2011. TREAT Asia HIV Observational Database (TAHOD) TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data collected from more than 5,500 patients at 22 clinical sites in 12 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. TREAT Asia Pediatric Network Representing more than 5,000 HIV-positive children in Asia, TREAT Asia's Pediatric Network includes 20 sites in seven countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database (TApHOD) was modeled on the adult TAHOD program, and includes data from approximately 4,000 pediatric patients at 16 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam. International AIDS Database TREAT Asia manages the Asia-Pacific section of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. To support IeDEA, TREAT Asia is contributing anonymous data from approximately 13,600 patients at 60 clinical centers in 13 countries within Asia and Australia. Investing in Adolescent Research TREAT Asia is currently supporting three studies that it hopes will inform and improve adolescent HIV treatment and care in Southeast Asia. This first is examining the incidence of human papillomavirus (HPV) infection?a precursor to cervical and anal cancer?in HIV-positive adolescents. A second study is assessing bone mineral density levels in children living with HIV and finding preliminary correlations between the use of antiretroviral therapy and bone density loss. The third study is using an audio-computer-assisted survey instrument (ACASI) to better understand how adolescents experience living with HIV by allowing them to anonymously respond to questions using a computer interface. Reaching Out to MSM In 2011, TREAT Asia became a proud co-sponsor of www.adamslove.org, a new non-commercial website providing HIV/AIDS information to men who have sex with men (MSM) in Thailand. An initiative of the Thai Red Cross AIDS Research Centre, Adam's Love innovatively combines education and entertainment, and is the first website of its kind in Southeast Asia. The website's creative team has partnered with amfAR to explore initiating a similar "edutainment" website in Indonesia. Exploring Links Between HIV and Cancer Among HIV-positive MSM, the risk of anal cancer is twice the level of those who are HIV-negative, but little research has been done on this issue in Asia. With funding from IeDEA, in 2009 TREAT Asia began supporting an innovative research study exploring the links between HIV and anal cancer and looking at cancer biomarkers in an attempt to better identify MSM with pre-cancerous anal lesions. Building Research Capacity TREAT Asia has implemented a research education program to help network members strengthen their skills in conducting clinical research and to boost the overall quality of care in the region. TREAT Asia organized 13 workshops and training sessions in 2011 including sessions on basic research skills (e.g., ethics, biosafety, research methods), laboratory training (e.g., HIV drug resistance testing), and clinical management of HIV (e.g., cancer, treatment failure, care of MSM). Building Community Treatment Literacy and Promoting Advocacy for Treatment Access Communicating treatment information about a disease as complex as HIV/AIDS can be daunting, but patients' lives depend on it. TREAT Asia works closely with regional organizations to support treatment literacy activities, including the production of "community friendly" educational brochures on HIV treatment standards in local languages. TREAT Asia also continues its partnership with UNAIDS, the Asia-Pacific Network of People Living with HIV/AIDS, the International Treatment Preparedness Coalition, and the Mdecins Sans Frontires Access Campaign. Through the Asia Treatment Working Group, TREAT Asia is part of a platform for promoting treatment access and higher quality HIV healthcare within the region. In 2011, TREAT Asia continued to publish lay-language articles about new research in the fields of prevention, treatment, and basic science. The goal of these articles is to explain HIV/AIDS research advances for people living with HIV/AIDS and their families, communities, and caregivers across Asia. The articles appear in the TREAT Asia Report and on TREAT Asia's website, www.treatasia.org. XVIII International AIDS Conference TREAT Asia was well represented at the International AIDS Society Conference in July 2011 in Rome, Italy, where several network members and partners presented their research findings. In addition, TREAT Asia was a scientific co-sponsor of the 3rd International Workshop on HIV Pediatrics, which preceded the conference. 14th Bangkok Symposium on HIV Medicine amfAR continued its support of this annual regional symposium, which was held in January 2011 and was organized by HIV-NAT, a TREAT Asia network site.
Program Service Accomplishments (4)	Part III, Line 4a-4d (4)	Line 4c: EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. amfAR25 amfAR commemorated 25 years of operation in 2011 and marked the occasion with a range of events and activities. The Foundation adopted the tagline "Making AIDS History" for the year and incorporated it into a special commemorative logo. Three short films were produced to commemorate the anniversary. One of them, narrated by amfAR Global Fundraising Chairman Sharon Stone, traced amfAR's history and showcased the Foundation's achievements. The other two were narrated by Vanessa Redgrave and paid tribute to the Foundation's founders - Dr. Mathilde Krim and Dame Elizabeth Taylor. Ironically, and tragically, Dame Elizabeth passed away in March of 2011. A special website - www.makingaidshistory.org - was created to capture the personal stories of a diverse group of people living with HIV from different backgrounds and different parts of the country. The site and the stories stimulated media interest and coverage of the individuals in local outlets in several parts of the country. Educational Materials amfAR produces a range of periodicals in both print and electronic formats, including its newsletter Innovations, published twice a year and distributed to more than 40,000 people; the TREAT Asia Report, published and distributed three times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to more than 40,000 people. The Foundation's website features news, interviews, and original articles covering science, policy, the global epidemic, and amfAR programs and activities. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues, and conducts public service advertising campaigns that have been instrumental in educating policy makers, healthcare professionals, people with HIV/AIDS, and the general public. Social Media amfAR vigorously expanded its presence in the social media arena, reaching large numbers of a people and a generally younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly added content to its Facebook page, mounted a campaign to increase Facebook followers, and live tweeted from fundraising and program events. It also expanded its YouTube channel content with a range of educational videos. Media Outreach amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS press coverage. Articles and reports involving amfAR-many of which included interviews with amfAR spokespeople-were carried in numerous media outlets, including The New York Times, The Wall Street Journal, the Washington Post, New York magazine, Reuters, Bloomberg News, and The Huffington Post. amfAR's leadership role in AIDS research was highlighted in late November 2010, when the iPrEx study results were released and outlets including The New York Times, The Wall Street Journal, the Financial Times, Agence-France Presse, and PBS NewsHour relied on amfAR CEO Kevin Frost or Vice President and Director of Public Policy for Chris Collins for commentary on what the results meant for the future of HIV/AIDS prevention and research. amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Fundraising Chairman Sharon Stone. In 2011, celebrity supporters included amfAR Ambassadors Cheyenne Jackson, Milla Jovovich, Liza Minnelli, and Michelle Yeoh, as well as Janet Jackson, Kylie Minogue, Dita Von Teese, Heidi Klum, Alan Cumming, Stevie Wonder, Gladys Knight, Dionne Warwick, Elton John, Richard Gere, Rosie O'Donnell, Whoopi Goldberg, Jennifer Hudson, John Legend, Andy Cohen, Diane Kruger, Kathy Griffin, Kim Cattrall, Stanley Tucci, and Rufus Wainwright.
Program Service Accomplishments (5)	Part III, Line 4a-4d (5)	THE MSM INITIATIVE: amfAR's MSM Initiative was launched in 2007 to respond to the alarmingly high rates of HIV among MSM, a group that in low- and middle-income countries is on average 19 times more likely to be infected than the general population. Stigma, discrimination, and legal prohibitions have fueled the spread of the epidemic among MSM, most of whom do not have access to HIV prevention, treatment, and care services. The MSM Initiative aims to reduce the spread and impact of HIV infection among MSM in resource-limited countries by providing support to grassroots groups through its community awards program. The program also works to raise awareness of HIV among MSM and to advocate increased funding for MSM-targeted services. Community Awards In 2011, amfAR awarded more than $775,000 to 44 groups in Africa, Asia and the Pacific, the Caribbean, Eastern Europe and Central Asia, and Latin America for a wide range of projects addressing HIV prevention, outreach, education, advocacy, testing, research, and capacity building. Africa amfAR awarded funding to eight groups in Africa: Humanity First Cameroon and Alternatives-Cameroun; an unnamed group in Ethiopia (name withheld by request); PEMA Kenya; Stop AIDS In Liberia; Association de lutte contre le sida (Morocco); Gender DynamiX (South Africa); and Gays and Lesbians of Zimbabwe. PEMA Kenya (Mombasa, Kenya) Building upon a previous amfAR award, PEMA Kenya is addressing stigma, discrimination, and criminalization of MSM and LGBT individuals among the religious community and media and law enforcement professionals in coastal Kenya. Emphasis is placed on the implications of stigma in accessing HIV prevention and treatment and other health services. Asia-Pacific Eleven organizations in Asia and the Pacific received community awards in two separate rounds of awards: Loving Support Center for Health and Education and another unnamed group in China; AIDS Task Force of Fiji; Sangama (India); Youth for Health Center (Mongolia); TLF Sexuality, Health and Rights Educators Collective, Incorporated (Philippines); The Human Rights Education Institute of Burma (Thailand); Beijing Ark of Love PLWHA Supporting Group (China); PT Foundation (Malaysia); AIDS Awareness Society (Pakistan); and Vietnamese Community Mobilisation Center for HIV/AIDS Control (Vietnam). Loving Support Center for Health and Education (China) This direct service intervention is promoting the health and rights of male sex workers in Shenyang and Tianjin. Employing a rights-based approach, the project empowers sex workers to assist and support each other, builds skills for health and well-being, and provides STI/HIV information and referrals. The project is also producing the first-ever male sex worker periodical in China. Caribbean Nine grassroots organizations in the Caribbean received amfAR funding: United Belize Advocacy Movement; Centro de Orientacin e Investigacin Integral in partnership with Jvenes de la Vida Real (Dominican Republic); GrenCHAP Inc. (Grenada); two unnamed organizations in Jamaica; United and Strong, Inc. (Saint Lucia); Foundation HE + HIV (Suriname); MSM: No Political Agenda and Friends For Life (Trinidad and Tobago). Friends For Life (Trinidad & Tobago) This project utilizes trained peer educators to increase access to sexual health services (including HIV voluntary counseling and testing) for LGBT individuals, other MSM, and transgender and male sex workers. Central to the project is the distribution of condoms, lubricant, safer sex information, and referral information cards. The project also collects baseline data on HIV/AIDS prevention knowledge among MSM, and provides one-to-one coping and life-skills counseling for gay men, other MSM, transgender individuals, and sex workers. Eastern Europe and Central Asia Nine groups in Eastern Europe and Central Asia received community awards from amfAR's MSM Initiative: We For Civil Equality (Armenia); Center for Information and Counseling on Reproductive Health - Tanadgoma (Georgia); Kyrgyz Indigo (Krgyzstan); The Siberian Alternative Center (Russia); Oryol Regional Public Organization to Fight AIDS, Phoenix PLUS (Russia); Non-Governmental Organization Safe Pulse of Youth (Serbia); Civil Society Organization Equal Opportunities (Tajikistan); Nikolaev Regional Public Youth Movement Penitentiary Initiative and NGO Insight (Ukraine). The Siberian Alternative Center NGO (Russia) Building upon a previous amfAR award, this project engages female friends of gay men, other MSM, and transgender individuals as counselors and educators. Taking advantage of the special relationship that exists between MSM/transgender individuals and their female friends, through training and regular meetings these women will assist in providing effective behavior change communication to reduce risky sexual behavior among MSM/TG. Latin America Seven organizations in Latin America received community awards: VIVO POSITIVO (Chile); Fundacin Radio Diversia (Colombia); Asociacin Jvenes en Movimiento (Honduras); SOMOSGAY (Paraguay); VA LIBRE in partnership with Asociacin Amigos por Siempre Promoviendo Tus Derechos AAxS (Peru); Instituto de Estudios en Salud, Sexualidad y Desarrollo Humano (Peru); Asociacin Civil Manantial de Vida Pro Defensa de los Derechos Humanos (Venezuela). Asociacin Civil Manantial de Vida Pro Defensa de los Derechos Humanos (Venezuela) This direct service intervention aims to empower young gay Yukpa men through skills-building workshops, discussion groups, and the development of a culturally appropriate HIV prevention and life skills handbook. Global Advocacy Corps Awards The Global Advocacy Corps is a small grants program shared by the Public Policy and MSM Initiative programs of amfAR. The advocacy work funded through this program emphasizes the use of new evidence and tools, and more strategic approaches to tackling the epidemic on a national level. It supports development of analyses and other writing, as well as follow-through advocacy with government, donors, and communities. A central goal of the awards is to affect national and donor policy: to make national responses to HIV/AIDS better funded, more strategic, more ambitious in terms of public health impact, and more focused on outcomes for individuals and communities affected by HIV/AIDS. It is expected that grantees draw on the latest research to make the case for new and smarter investments to improve HIV-related results. Two Global Advocacy Corps awards totaling $40,000 were made to groups in Kenya and Namibia in 2011. Publications As part of its efforts to raise awareness among governments, donors, and international nongovernmental organizations of the spread of HIV among MSM and to advocate effective strategies for addressing it, amfAR publishes reports on HIV and MSM. In 2011, the MSM Initiative staff worked with the Policy team and colleagues at Johns Hopkins University to compile and edit an MSM global report-titled "Achieving an AIDS-Free Generation for Gay Men and Other MSM"-which finds that resources dedicated to addressing the epidemic among MSM are grossly insufficient, and that funding intended for this population is often diverted away from MSM-related services. The report was released in 2012.
Program Service Accomplishments (6)	Part III, Line 4a-4d (6)	public policy: Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation is engaged in efforts to secure necessary increases in funding for HIV/AIDS research; implement the new National HIV/AIDS Strategy; expand access to care and treatment; and protect the civil rights of all people affected by HIV/AIDS. Capitol Hill AIDS Summit Spearheaded by Senior Medical and Policy Advisor Susan Blumenthal, amfAR brought together many of the biggest names in HIV research, policy, and advocacy for a half-day conference that filled the Senate Kennedy Caucus Room to capacity. Speakers and panelists included Dr. Anthony Fauci of the National Institutes of Health; Melody Barnes, director of the White House Domestic Policy Council; Dr. Michel Kazatchkine, executive director of the Global Fund; and Dr. Margaret Hamburg, commissioner of the FDA. Speakers discussed ideas and strategies for halting the epidemic, and Whoopi Goldberg, Cokie Roberts, and Chris Matthews lent their star power to help focus the day's message: ending the AIDS epidemic. House Democratic Leader Nancy Pelosi (D-CA), along with Reps Barbara Lee (D-CA), Henry Waxman (D-CA), Nita Lowey (D-NY), and Jim Himes (D-CT), as well as Senators Kirsten Gillibrand (D-NY) and Mike Enzi (R-WY) all made appearances to strongly voice their continued support for amfAR and the fight against AIDS. Harm Reduction As one of the earliest supporters of comprehensive harm reduction programs for injection drug users (IDUs), including syringe exchange, amfAR has played a leading role in advocating the implementation of these lifesaving programs. In December 2009, the Foundation celebrated a major victory on this front when Congress lifted the ban on federal funding for syringe exchange programs (SEPs). However, in anticipation of a House proposal to reinstate the ban on federal funds for syringe access, amfAR's public policy office worked throughout1 2011with Senate Foreign Operations and Financial Services staff and Senator Sherrod Brown's office on this issue. amfAR staff made a presentation on US drug policy and organized a meeting of PEPFAR intravenous drug users (IDU) implementers at the Beirut Harm Reduction Conference. And in March, the policy team organized and attended meetings with staff to key Senators and House Minority Leader Pelosi. Also in March, amfAR staff hosted a strategy meeting in Congress on syringe exchange. amfAR funds the only annual national survey of U.S. SEPs, which is traditionally published in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report (MMWR). Under contract with the New York State Department of Health's AIDS Institute, amfAR continued to administer the distribution of harm reduction supplies to the 20 authorized SEPs statewide, which have served more than 155,000 registered participants. Shaping the Domestic Response to HIV/AIDS amfAR has long advocated the implementation of a comprehensive national HIV/AIDS strategy to address the ongoing epidemic in the U.S., where more than one million people are living with the virus. In 2011, public policy staff members attended a U.S. Department of Health & Human Services (HHS) meeting on redesigning reporting requirements for federal grant recipients so they are aligned with the national strategy, which was unveiled by the White House in July 2010 and emerged with help from the HIV/AIDS advocacy community. amfAR staff also spearheaded a sign-on statement-signed by more than 140 organizations-supporting the national strategy and laying out several principles for its success, including calls for expanded services and protection of Medicaid expansion and health reform. Public policy staff were also featured in a White House video on the first anniversary of the national strategy. Global Health In 2011, public policy staff worked with fellow AIDS advocates to argue against funding cuts for global HIV/AIDS initiatives, including the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria, and focused on the need to scale up HIV prevention efforts, both domestically and globally, as an effective way to combat the worldwide AIDS epidemic. In addition to meeting with key administration officials and members of Congress, amfAR released a series of publications arguing against the case for cutting global AIDS funding. In July 2011, the Foundation released two new issue briefs: "Ending the HIV/AIDS Epidemic" drew on the latest research to make the case that with strategic investments we can make great strides against the epidemic; "FY12 Global Health Funding Proposals: Projecting the Human Impact" estimated the human impact of various budget scenarios. In February, the public policy office released a report showing the potential human impact of global health funding cuts as proposed in September 2010 by House Minority Leader John Boehner. Vertical Transmission Preventing hundreds of thousands of HIV-positive mothers from passing the virus to their children "is one of the startling successes in the response to the global AIDS epidemic," said amfAR Vice President and Director of Public Policy Chris Collins in his opening remarks at an amfAR-sponsored Capitol Hill briefing on January 31. Recognizing these extraordinary gains-and the imperative of extending these gains further-a panel of experts at the Washington, D.C., briefing highlighted the challenges to fully eradicating mother-to-child HIV transmission The briefing brought together experts from the U.S. government, foundations, and NGOs that sponsor prevention of mother-to-child transmission (PMTCT) services. MSM amfAR's policy office works closely with the MSM Initiative to advocate expanded access to HIV prevention and treatment services for MSM worldwide, and to fight the stigma and discrimination that make MSM more vulnerable to HIV infection and inhibit equal access to care. Working with Trust for America's Health, amfAR released an issue brief proposing "A New HIV Prevention Paradigm for Gay and Bisexual Men in the U.S.," emphasizing efforts to address the context of risk, including expanded HIV treatment access to reduce community viral load, and anti-discrimination, anti-stigma, and anti-bullying efforts. Policy staff also co-sponsored, with Advocates for Youth, a community forum on Sexual Rights and HIV Prevention in Nigeria featuring activist Stephen Chukwumah and presented at a COC Netherlands conference in Moldova on opportunities for funding and policy change for LGBT groups in the region. When Ugandan MSM advocate David Kato was brutally murdered in January, amfAR put out a release calling for an independent investigation and policy staff utilized social media to call on the US State Department to press the Ugandan government to fully investigate the murder. A "Prevention Revolution" Advocating increased funding for lifesaving HIV/AIDS research is another of amfAR's policy priorities. In March 2011, amfAR sponsored a Capitol Hill briefing-titled "Accelerating an HIV Prevention Revolution: A Roadmap"-that was attended by more than a dozen leading government, research, policy, and medical experts. Citing major advances during the past year in pre-exposure prophylaxis (PrEP) and microbicide trials, strides in vaccine research, the use of social media, and treatment as a means of preventing viral transmission, the speakers-including high-level representatives from the Centers for Disease Control and Prevention (CDC), UNAIDS, the National Institutes of Health (NIH), and the San Francisco Department of Public Health-stressed that, 30 years into the epidemic, the world finds itself in a new era of prevention. Many of the speakers touched on the global application of new HIV prevention techniques, and underscored the importance of further study and funding for these initiatives. Pre-Exposure Prophylaxis Pre-exposure prophylaxis (PrEP)-which involves giving antiretroviral therapy to HIV-negative people at high risk of becoming infected-holds great promise as a potential prevention intervention. In 2011, amfAR, as part of a coalition of partners, organized and participated in calls, meetings, and forums while continuing to encourage regulatory approval of PrEP for MSM domestically.
Policies	Form 990, Part VI, Section B	Line 11 - The Form 990 was prepared by a nationally renowned accounting firm in conjunction with the organization's financial department. A copy of the draft Form 990 was circulated to the full Board of Trustees for discussion and comment. Each Board Member was provided ample opportunity to comment on the information contained in the 990 prior to its filing with the Internal Revenue Service. Line 12 - Each officer, director, trustee and key employee of amFar ("foundation") is required to annually disclose any conflicts of interest that arise by virtue of employment, board service, or position with the foundation. The foundation monitors compliance with its conflict of interest policy through an annual questionnaire/disclosure statement that is distributed to these individuals. Potential conflicts are investigated immediately. LINE 15 -AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS.
Disclosure	Form 990, Part VI, Section C	LIne 19 - amfar makes its Form 990 available to the public by retaining a copy at its place of business and on its website, www.amfar.org. The Form 990 is likewise published on the internet at www.guidestar.org. The Foundation's financial statements are made available in its annual report and on its website. The Foundation's governing documents and conflict of interest policy are not ordinarily made available to the public, but, if requested, will be provided at management's discretion.
Functional Expenses	Part IX, Lines 1 & 3	The Foundation for AIDS Research reports its grants net of grant returns or recoveries. Periodically, grants remitted to charitable organizations are returned to AMFAR for a variety of reason. On Schedules F & I, grants are reported irrespective of whether they were ultimately returned to AMFAR since categorizing the "returned" amounts would be time consuming. Therefore, amounts reported on Part IX, Line 1 will not tie to total grants on Schedule I; amounts reported on Part IX, Line 3 will not tie to total grants on Schedule F.
Other Changes in Net Assets	FORM 990, SECTION XI, LINE 5	UNREALIZED LOSS.............(465,956) OTHER CHANGES................135,728 ------------ TOTAL LINE 5 (330,228) ============